# US 2015/0105355 A1 · 4-dedimethylamino tetracycline compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105355 A1
- Document ID: US20150105355A1
- Status: Published application
- Kind: A1
- Application number: 14/176,923
- Filed: 2014-02-10
- Published: 2015-04-16
- Earliest claimed: 2002-01-08
- Assignees: Paratek Pharmaceuticals, Inc.
- Applicants: Paratek Pharmaceuticals, Inc.
- Inventors: Mark L. Nelson; Kwasi Ohemeng
- Web page: https://patentgrep.com/patent/US20150105355A1

## CPC

- A61K 31/65: Tetracyclines
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61P 15/02: for disorders of the vagina
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 235/70: having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C 237/26: of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
- C07C 251/48: with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
- C07C 255/41: the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 271/54: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 271/58: with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C 275/42: being further substituted by carboxyl groups
- C07C 275/54: Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
- C07C 279/18: having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
- C07C 311/06: to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 333/08: having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
- C07C 335/22: being further substituted by carboxyl groups
- C07C 381/10: Compounds containing sulfur atoms doubly-bound to nitrogen atoms
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/185: from aliphatic carboxylic acids
- C07D 317/60: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07F 9/2475: {of aralkylamines}
- C07F 9/4006: {Esters of acyclic acids which can have further substituents on alkyl}
- C07C 2601/08: the ring being saturated
- C07C 2601/10: the ring being unsaturated
- C07C 2601/16: the ring being unsaturated
- C07C 2603/46: 1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for treating a tetracycline responsive state in a subject in need thereof, the method comprising administering to said subject a tetracycline compound of the following structural formula:
such that said subject is treated.

### Claim 12 (depends on 11)

The method of claim 11, wherein said subject is a human.

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The method of claim 11, wherein the tetracycline responsive state is not a bacterial infection.

### Claim 15 (depends on 11)

The method of claim 11, wherein the tetracycline responsive state is an inflammatory process associated state.

### Claim 16 (depends on 15)

The method of claim 15, wherein the inflammatory process associated state is rheumatoid arthritis.

### Claim 17 (depends on 15)

The method of claim 15, wherein the inflammatory process associated state is gastroenteritis or colitis.

### Claim 18

A method for treating a tetracycline responsive state in a subject in need thereof, the method comprising administering to said subject a pharmaceutical composition comprising a tetracycline compound of the following structural formula:
and a pharmaceutically acceptable carrier, such that said subject is treated.

### Claim 19 (depends on 18)

The method of claim 18, wherein said subject is a human.

### Claim 20 (depends on 18)

The method of claim 18, wherein the tetracycline responsive state is not a bacterial infection.

### Claim 21 (depends on 18)

The method of claim 18, wherein the tetracycline responsive state is an inflammatory process associated state.

### Claim 22 (depends on 21)

The method of claim 21, wherein the inflammatory process associated state is rheumatoid arthritis.

### Claim 23 (depends on 21)

The method of claim 21, wherein the inflammatory process associated state is gastroenteritis or colitis.
